Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis

• Published in: Frontiers in endocrinology (Lausanne) Vol. 13; p. 850836
• Main Authors: Wei, Wen, Liu, Jin, Chen, Shiqun, Xu, Xinghao, Guo, Dachuan, He, Yibo, Huang, Zhidong, Wang, Bo, Huang, Haozhang, Li, Qiang, Chen, Jiyan, Chen, Hong, Tan, Ning, Liu, Yong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 07.03.2022
• Subjects: cardiorenal outcomes; coronary artery disease; Coronary Artery Disease - complications; Coronary Artery Disease - drug therapy; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Endocrinology; Heart Failure - complications; Humans; improve; meta-analysis; sodium glucose cotransporter type 2 inhibitors; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; coronary artery disease; meta-analysis; improve; sodium glucose cotransporter type 2 inhibitors; cardiorenal outcomes
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2022.850836

Sodium glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), heart failure (HF) or chronic kidney disease (CKD). However, whether or not the patients with coronary artery disease (CAD) have prognostic benefit from SGLT-2i treatment has not been fully studied. The purpose of this meta-analysis is to determine the prognostic benefit of SGLT-2i administration in CAD patients. We searched the PubMed, Embase and Cochrane Library from inception until October 15, 2021. We included randomized controlled trials (RCTs) reporting the effect of SGLT-2i on major adverse cardiovascular event (MACE), hospitalization for heart failure (HHF), cardiovascular (CV) death and cardiorenal parameters in CAD patients. Hazard ratio (HR) with 95% confidence interval (CI) and mean difference (MD) from trials were meta-analyzed using fixed-effects models. Nine trials enrolling 15,301 patients with CAD were included in the analyses. Overall, SGLT2i were associated with a reduced risk of MACE (HR: 0.84; 95% CI 0.74-0.95; I = 0%), HHF (HR: 0.69; 95% CI 0.58-0.83; I = 0%) and a composite of CV death or HHF (HR: 0.78; 95% CI 0.71-0.86; I = 37%) in CAD patients. Compared with control group, estimated glomerular filtration rate (eGFR) level decreased less in SGLT-2i group (mean difference [MD] = -3.60, 95% CI, -5.90 to -1.30, p = 0.002; I = 0%). SGLT-2i can improve cardiorenal outcomes in CAD patients. Further RCTs and real world studies are need to investigate the effect of SGLT2i on CAD patients. PROSPERO, CRD42021258237.